A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Clinical trial NCT04181827 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04181827
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-12
- Primary completion
- 2024-05-01
- Enrollment
- 419
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.